Floatz logo

Ibrutinib

Immunoproliferative Disorders

Oncternal Therapeutics, IncSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Tucidinostat
Fudan University
Phase 2CCC
Atlcar.Cd30.Ccr4 Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Bendamustine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 12 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →